ATLANTA, March 18, 2026 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (the “Company”), a development-stage biotechnology company developing new medicines to treat pain and neuropathy,...
- Low early termination rate (4.3%) among the first 116 patients completing the study suggests Halneuron ® treatment to be well tolerated - ATLANTA, Feb. 02, 2026 (GLOBE NEWSWIRE) -- Dogwood...
Pricing of $12.5 Million Registered Direct Offering & Concurrent Private Placement Offerings priced at-the-market under Nasdaq rules ALPHARETTA, Ga., Jan. 12, 2026 (GLOBE NEWSWIRE)...
- Halneuron ® treated patients separating from placebo on pain improvement assessment; Company expects top-line results availability in Q3 2026 - - The overall study dropout rate of ~4.4% is far below...
- Enrollment to date of 100 patients, with 80 patients completing treatment in the ongoing Halneuron ® Phase 2b trial, prespecified interim analysis remains on track for Q4 2025 release - - Secured...
Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Dogwood Therapeutics...
-A first-in-class LRP1 agonist, SP16 phase 1b Chemotherapy Induced Neuropathy (CIPN) Study fully funded by the National Cancer Institute, with projected patient enrollment beginning in the first half...
ATLANTA, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (the “Company”), a development-stage biotechnology company developing new medicines to treat pain and fatigue-related...
- Enrollment to-date of 52 patients in the ongoing Halneuron ® Phase 2b Trial - - Halneuron ® Chemotherapy-Induced Neuropathic Pain (“CINP”) Phase 2b study interim data readout remains on track...
- Halneuron ® Chemotherapy-Induced Neuropathic Pain (“CINP”) Phase 2b study interim data readout remains on track as projected for Q4 2025 - - Low discontinuation rate (6%) due to adverse events...